Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Mantle cell lymphoma (MCL) is an aggressive and incurable lymphoma. Standard of care for younger patients with MCL is induction chemotherapy followed by autologous stem cell transplantation (auto-HCT). Rituxim...

Source: Journal of Hematology and Oncology - June 28, 2018 Category: Hematology Authors: Robert W. Chen, Joycelynne M. Palmer, Sarah Tomassetti, Leslie L. Popplewell, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, Tanya Siddiqi, Ni-Chun Tsai, Lu Chen, Fay Zuo, Rosemarie Abary, Ji-lian Cai, Alex F. Herrera, John J. Rossi, Steven T. Tags: Research Source Type: research